Brickell Biotech Inc

Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in September 2009 and is headquartered in Boulder, CO.

Cardiff Oncology

MEI Pharma

Sesen Bio Inc.

Biotech penny stocks to watch in June. The post Top Penny Stocks To Buy?

Top Penny Stocks To Buy? 4 Biotech Stocks To Watch Now

– BBI-02 is a potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation and broad potential to treat debilitating autoimmune and inflammatory diseases –

Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02

Brickell (BBI) delivered earnings and revenue surprises of -33.33% and 52.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Brickell (BBI) Reports Q1 Loss, Lags Revenue Estimates

Brickell Biotech, Inc. (NASDAQ:BBI ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Garth Russell - IR, LifeSci Advisors Robert Brown - Chief Executive Officer Andrew Sklawer - Co-Founder and Chief Operating Officer Albert Marchio II - Chief Financial Officer Monica Luchi - Chief Medical Officer Conference Call Participants Trevor Allred - Oppenheimer Operator Greetings and welcome to Brickell Biotech Inc. Quarter 1, 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Brickell Biotech, Inc.'s (BBI) CEO Robert Brown on Q1 2022 Results - Earnings Call Transcript

Completed sale of sofpironium bromide to Botanix Pharmaceuticals for up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and sales milestone payments, plus tiered earnout payments on net sales

Brickell Biotech Reports First Quarter 2022 Financial Results and Provides Corporate Update

BOULDER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, announced today that it will report its first quarter financial results on Thursday, May 12th. Brickell's management will host a conference call and webcast at 4:30 p.m. EDT that same day to discuss the financial results and recent corporate highlights.

Brickell Biotech to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12, 2022

Brickell Biotech Inc (NASDAQ: BBI) agreed to sell sofpironium bromide rights to Australia-based Botanix Pharmaceuticals Limited. Brickell will receive upfront and potential near-term regulatory milestone payments over the next 18 months of up to $9 million.

Brickell Biotech Shares Surge After Offloading Late-Stage Asset To Australia-Based Firm

Meeting adjourned to May 17, 2022 at 10 a.m. MT

Brickell Biotech Announces Adjournment of Annual Meeting of Stockholders

Deal includes up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and sales milestone payments, plus tiered earn out payments on net sales to Brickell

Brickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharmaceuticals

Acutus Medical

Histogen

Idera Pharmaceuticals

Synthetic Biologics

Top penny stocks to watch under $1 in April if you like Biotech stocks. The post 5 Top Biotech Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Top Biotech Penny Stocks Under $1 To Watch This Week

Here is how Brickell (BBI) and Eli Lilly (LLY) have performed compared to their sector so far this year.

Has Brickell Biotech (BBI) Outpaced Other Medical Stocks This Year?

Agile Therapeutics

IT Tech Packaging Inc

Palatin Technologies

Popular Reddit penny stocks to watch under $1. The post Best Penny Stocks Today?

Best Penny Stocks Today? 4 To Buy For Under $1 According To Reddit

Akebia Therapeutics

Borqs Technologies

PolarityTE Inc

Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 5 Stocks Under $1 To Watch In April

Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q4 2021 Results - Earnings Call Transcript

Brickell (BBI) delivered earnings and revenue surprises of 33.33% and 49.52%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Brickell (BBI) Reports Q4 Loss, Misses Revenue Estimates

Broadened strategic focus and expanded pipeline in immunology and inflammation following acquisition of rights to BBI-02, a potential first-in-class oral DYRK1A inhibitor, a portfolio of novel STING inhibitors, and a next-generation kinase inhibitor platform

Brickell Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

BOULDER, Colo., March 10, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory and other debilitating diseases, announced today that results from the US Phase 3 pivotal Cardigan I and Cardigan II studies of sofpironium bromide gel, 15% in primary axillary hyperhidrosis patients were selected for an oral presentation at the Late-Breaking Research session during the American Academy of Dermatology's (AAD) 2022 Annual Meeting, which is being held from March 25-29 in Boston, MA.

Brickell Biotech Selected for a Late-Breaking Oral Presentation of US Phase 3 Pivotal Cardigan I and Cardigan II Study Results for Sofpironium Bromide Gel, 15% at the 2022 AAD Annual Meeting

BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory and other debilitating diseases, announced today that it will report its fourth quarter and full year 2021 financial results on Tuesday, March 15th. Brickell's management will host a conference call and webcast at 8:30 a.m. EDT that same day to discuss the financial results and recent corporate highlights.

Brickell Biotech to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 15, 2022

Brickell Biotech Inc BBI has entered into an exclusive agreement with Carna Biosciences Inc to develop and commercialize Carna's portfolio of oral Stimulator Interferon Genes (STING) antagonists.  Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

Brickell Biotech, Carna Biosciences Ink Licensing Pact For STING inhibitors

Lead STING inhibitor candidate, BBI-10, demonstrated dose-dependent cytokine reduction in nonclinical in vitro and in vivo studies providing strong proof-of-mechanism

Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune and Inflammatory Diseases from Carna Biosciences

Farmmi

Immuron

Check these three penny stocks out for your watchlist right now The post Best High Volume Penny Stocks to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best High Volume Penny Stocks to Watch Right Now

Brickell (BBI) delivered earnings and revenue surprises of -45.45% and -56.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Brickell (BBI) Reports Q3 Loss, Misses Revenue Estimates

Brickell Biotech, Inc. (BBI) CEO Rob Brown on Q3 2021 Results - Earnings Call Transcript

Announced positive topline results from the Phase 3 pivotal clinical studies of sofpironium bromide gel, 15% in primary axillary hyperhidrosis patients; plan to submit a New Drug Application (NDA) to the FDA in mid-2022

Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Update

BOULDER, Colo., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, announced today that it will report its financial results for the third quarter, ended September 30, 2021. Brickell's management will host a conference call and webcast at 4:30 pm ET on Tuesday, November 9th to discuss the financial results and recent corporate highlights.

News for Brickell Biotech Inc Stock (BBI)